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ABSTRACT 
 
 
 Rac1 is a member of a family of small GTPases that are primarily responsible for 
cellular motility and morphology. Activation of Rac1 by Rac-specific guanine nucleotide 
exchange factors (GEFs) is thought to be important for the metastasis of cancer cells. The 
scope of this project was to synthesize a minimal extended peptide sequence that would 
block interaction between Rac1 and the Rac1-specifice exchange factor GEF-H1. 
Inhibition of Rac1 activation by Rac-specific GEFs would be a useful tool for the study 
of Rac-mediated cellular processes and may ultimately result in cancer therapeutics.  
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BACKGROUND 
 
 
 
GTPases 
 
 GTPases are a large family of proteins that hydrolyze guanosine triphosphate 
(GTP) into guanosine diphosphate (GDP).  The function of a GTPase at any given time is 
determined by the nucleotide to which it is bound. When a GTPase is bound to GDP it is 
in its “off” form and is unable to bind effectors. Binding GTP turns it “on” and allows 
effectors to bind. Most effector proteins are autoinhibited; the binding of these proteins to 
GTP bound GTPases activates the effector and enables it to perform biological effect 
such as rearrangement of the actin cytoskeleton. The switch between active and inactive 
forms can be seen by certain conformational changes that take place when the protein 
binds GTP. The process of switching GDP for GTP is mediated by a guanosine 
nucleotide exchange factor (GEF). The GEF allows the transfer of a GTP to replace GDP 
so that the GTPase is effectively reloaded. At this point the GTPase is free to hydrolyze 
the GTP, a process helped along by GTPase activating proteins, or GAPs. GAPs increase 
a GTPases’ intrinsic hydrolysis rate by forming a more stable transition state.  
 GTPases of the Ras superfamily contain two distinct regions that change 
conformation upon binding GTP. These regions are known as switch I and switch II. 
Switch I is an extended structure that participates in binding Mg
2+
. The conformation of 
switch II is a loop attached to a helix (Fig. 1, left panel, white and red) [11]. These both 
undergo conformational changes that facilitate binding of effectors. When bound to GDP, 
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the switches are flexible and loose. After binding GTP, however, the structures become 
rigid and well defined (Fig. 1, right panel). 
 
 
Figure 1: Cdc42 (left panel) and Cdc42 in complex with the GTPase binding domain of ACK, an 
effector protein  (right panel).   Switches I & II are both shown in white (left) and red (right).  White 
represents random coil structure, red represents fixed structure. From Owen et al [8]. 
 
Between switch I and II in Rac are two β strands, β2 and β3 (See Fig. 2).  These β 
strands have an extended conformation that resembles a flat sheet. Since the 
GTPase/effector interface has this specific conformation a mimicking molecule that 
displays this type of structure would be a good candidate for competitive inhibition. 
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Figure 2: Switches and β-sheets of Rac1.  Switch I shown in red; β2 shown in orange; β3 shown in 
yellow; switch II shown in blue; rest of Rac1 shown in gray. 
 
Rho GTPases 
 The Rho family is comprised of 20-30 kDa GTPases and includes isoforms of 
Rho, Rac and Cdc42 among others. Rho GTPases have a large variety of functions in the 
cell including organization of actin filaments, signal transduction pathways, and making 
up components of larger complexes such as NADPH oxidase. This variety of functioning 
is due to the fact that there are approximately 22 Rho family GTPases, 80 GAPs and 80 
GEFs. The three GTPases mentioned in Figure 3 (Rho, Cdc42, and Rac) are among the 
most thoroughly studied of the Rho family. The number of biological effects that any one 
GTPase may have shows the importance of specificity relating to these molecules. For 
example, Cdc42 and Rac have approximately 70% sequence homology [3]. It is not 
surprising that they share several effectors, exchange factors and GAPs. Despite their 
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similarities, there are also regulatory molecules that react specifically with either Cdc42 
or Rac. These are the molecules of the most interest in this study.    
 
Figure 3: Biological Pathways Induced by Various Rho Family Members.  The table shows various 
pathways that are regulated by Rho, Rac and Cdc42 [1]. 
 
 As can be seen from Figure 3 Rac and Cdc42 are very similar in function yet still 
display some specificity, for example only Rac is present in NADPH oxidase and only 
Cdc42 shows an effect on cell polarity. One important role of Rac and Cdc42 is their 
effects on the actin cytoskeleton. Rearrangements of the actin cytoskeleton allow for 
cellular motility [12]. Lamellipodia and filopodia are cellular protrusions of the 
cytoskeleton which allows for cell motility; these are controlled by Rac1 and Cdc42 
respectively. Cellular motility is important to biological process such as wound healing 
and angiogenesis. Metastasis, the movement of cancerous cells through tissues, relies 
heavily on lamellipodia/filopodia formation. This identifies Rac and Cdc42 as possible 
targets for prevention of cancer metastasis [14].  
 
Guanosine Nucleotide Exhange Factors (GEFs) 
 There are at least three GEFs that interact specifically with Rac and not Cdc42. 
These are of particular interest considering there are such similarities between Rac and 
Cdc42’s binding interactions. The GEFs are TiamI, Trio and GEF-H1 (which also binds 
Rho A, B and C). Each of these GEFs contains a certain sequence homology that has 
been shown to influence binding specificity and catalytic function. This similarity in 
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sequence is composed of two domains, the Dbl homology (DH) and the pleckstrin 
homology (PH). The PH domain almost always follows the Dbl domain, and the two 
together have been found to be the minimal sequence required for full GEF functionality 
[3,15]. While the DH domain seems to be the necessary domain for nucleotide exchange, 
the PH domain seems to both enhance the exchange process and specificity as well as 
influence cellular localization [10]. The crystal structure of the DH/PH domain of TiamI 
in complex with Rac1 has recently been published [13]. From this crystal structure one 
can identify the points of interaction between the two proteins. 
  
 
Figure 4: Crystal Stucture Model for the Interaction of Rac1 with GEF TiamI.  The DH domain of 
TiamI (yellow) shows several contacts with Rac1 (red). The PH domain (blue) shows no visible 
contacts. 
 
Figure 4 shows that there is no interaction between Rac1 and the PH domain (blue) of 
TiamI and there is also only a small area that interacts with the DH domain (~residues 
52-60 of Rac1) .  
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Rac Specific GEF Inhibitory Peptide 
 Gao et al. set out to determine which sections of Rac1 are necessary for 
specificity and binding to Tiam1, Trio and GEF-H1. This study was done before the 
crystal structure of Rac1/Tiam1 was published so it was not clear what sections of the 
proteins were interacting. They began their study by running simple assays to determine 
GEF nucleotide exchange activity on Rac1 and Cdc42. Figure 4 shows their results which 
clearly indicate that all their GEFs bind specifically to Rac1 only.  
 
Figure 5: Results of GEF binding specificity. Decrease in fluorescence shows exchange of MANT-
GDP for GTP and therefore indicates GEF activity. From Gao et al [3]. 
 
Due to the amount of evidence that shows switch I & II to be of high importance to 
binding, the researchers next made point mutations to both regions. They found that 
mutations of certain residues in both sections resulted in the inability to bind GEFs and 
the loss of ability to exchange nucleotide once bound. 
 Although these residues are important to GEF binding and activity, it is not likely 
that they allow for specificity between Rac and Cdc42. The reason for this is that switch I 
& II are highly conserved across most GTPases, especially between Rac and Cdc42. The 
only difference between switch I & II of Rac and Cdc42 is at residue 33; in Rac it is an 
isoleucine, in Cdc42 a valine, a highly conservative substitution [7]. To test for residues 
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that determine specificity a series of Rac1/Cdc42 chimeras (Fig. 6) were tested for their 
ability to bind GEF’s. The assumption was that any chimera that contained the necessary 
sequence from Rac1 would bind GEFs. 
 
 
Figure 6: Schematic representation of tested Rac1/Cdc42 chimeras. The dark areas 
indicate the amino acid residues from Rac1; white designates residues from Cdc42.   
From Gao et al [3]. 
 
They found that chimeras containing residues 53-70 of Rac1 were able to bind and 
function, whereas chimeras lacking this sequence could not. 
 Next they determined which residues of this sequence were important to 
specificity between Rac and Cdc42. This was a relatively easy problem to solve because 
the only residue that is different between the two GTPases in this range is 56 which is a 
tryptophan in Rac1 and a phenylalanine in Cdc42. The crystal structure of Rac1 
associated with TiamI shows that the W56F mutation results in the loss of a hydrogen 
bond to His1178 of TiamI. There is also a loss of a considerable amount of Van der 
Waals interactions due to the loss of the indole side chain of the tryptophan. 
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Figure 7: Left image shows wild type Rac in complex with GTPase binding domain of TiamI. Right 
image shows Rac1 W56F mutant in complex with the GTPase binding region of TiamI [13]. 
 
Since it appeared that Trp56 was the only residue that provided specificity between Rac1 
and Cdc42, the researchers tested Rac1 W56F vs. Cdc42 F56W. The results showed no 
binding of GEFs to Rac1 W56F, but binding similar to that of wild type Rac1 by Cdc42 
F56W. 
 Finally, they constructed two Rac1 based peptides to use for testing in an 
inhibition assay. The peptides were identical to residues 45-60 of Rac1 except in one the 
W56F mutation was made. Results showed a dose-dependent inhibition of Rac1 binding 
to Trio, TiamI and GEF-H1 when treated with the peptide containing Trp56. There was 
no inhibition by the Phe56 peptide [3]. 
 The crystal structure of residues 45-60 of Rac1 in complex with TiamI is shown 
in Figure 8. The conformation is such that residues 45-51 are coiled and make no 
apparent contact with TiamI. Residues 52-60, however, adopt an extended conformation 
and have three points of contact with TiamI; Asn52, Trp56 and Gly60. Since these appear 
to be the main contact points of Rac1 to TiamI it should be possible to truncate this 
peptide to residues 52-60 and still retain the ability to inhibit interaction.  
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Figure 8: Residues 45-60 of Rac1 (red) in complex with the GTPase binding domain of Tiam1 (blue). 
 
 
Furthermore, since Trp56 has been determined as the only residue to determine GTPase 
specificity, [3] it may also be possible to truncate even further depending on the roles of 
Asn52 and Gly60. There is also the potential to increase inhibition efficiency by 
modifying the peptide so that it always exhibits an extended conformation similar to that 
seen at the binding interface.  
 
N-Methylated Peptides 
 The conformation of a peptide is very important to how active it is biologically 
[9]. While short peptides are generally unstructured, the conformation can be specifically 
hindered such that it gives a desired structure. These hindrances come primarily from 
amino acid side chains and alterations of groups that prevent rotation around peptide 
bonds. N-methylated amino acid substitutions have been shown to restrict the altered 
amino acid and the one preceding it to an extended conformation. N-methylation is done 
by replacing the amide hydrogen on a residue with a methyl group. Doing this locks the 
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conformation of the modified amino acid as well as the residue that precedes it [9]. 
Alternating sites of N-methylation, then, should lock the entire peptide in an extended 
conformation. Gordon et al. used this alternating N-methylation strategy when they 
constructed a peptide to inhibit Aβ1-40 fibrillogenesis. 
 Gordon et al. synthesized a five amino acid sequence comprised of Aβ16-20. 
They also synthesized the same sequence containing alternating N-methylations. The 
structure of these sequences was determined by circular dichroism, a method that 
measures the ellipticity of light. The spectra obtained showed that the methylated version 
of the peptide was a β-strand; the un-methylated version showed characteristics of a 
random coil [4]. 
 Some other important characteristics arise because of N-methylation. These 
include increased cell permeability and reduced susceptibility to proteolysis both of 
which increase potential as inhibitory molecules in live cells. The reason these 
characteristics show up is because N-methylation reduces the number of available 
hydrogen bond donors (Fig. 9) [4]. 
 
Figure 9: The top image is of an N-methylated peptide (K(Me)LV(Me)FF). The bottom image is of 
the same peptide sequence (KLVFF) with no methylation. From Gordon et al. 
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A peptide has to be desolvated of the water that is hydrogen bound to it before it can pass 
through the membrane. Reducing the amount of hydrogen bond donors reduces the 
energy required to desolvate the peptide and therefore increases its chances of crossing 
the membrane. Alternating N-methylation also produces a chain with two faces. On one 
face of the peptide there is normal bonding capabilities contributed from side chains and 
amide hydrogens; this face should function like a normal peptide chain. The second face 
has lost the hydrogen bonding capabilities of the amide hydrogens because they have 
been replaced by methyl groups which make no such hydrogen bonds. Removal of these 
hydrogen bond donors greatly changes the way this face interacts. The loss of hydrogen 
bonding capabilities also makes the molecule more hydrophobic. Gordon et al. also 
studied this aspect and found that N-methylated derivatives of their peptide were able to 
make it into cells while un-methylated versions could not [4]. These N-methylated 
peptides should also make for good inhibitors of intracellular β-strand interactions 
because of their extended conformation and increased cell permeability. 
 The design of a minimal peptide domain that will specifically inhibit GEF-H1’s 
binding capabilities to Rac1 should incorporate all of these features. Since residues 45-51 
of Rac1 make no contacts with the DH/PH domain of TiamI they should be able to be 
removed with little to no effect on inhibition. It is also likely that other truncation of 
residues 52-60 could be made and still be effective as long as they contain Trp56. Since 
residues 52-60 of Rac1 adopt a β-strand conformation when in complex with TiamI, it is 
likely that an N-methylated version of the inhibitory peptide would be more effective. If 
the peptide were already in an extended conformation the entropic cost of changing to an 
extended conformation would be reduced, so binding to the peptide would be favored.  
 17 
N-methylation should also make the inhibitory peptide cell permeable and useful for in 
vivo assays. Given the information collected, construction of a truncated, Rac1 derived, 
N-methylated peptide sequence should provide better inhibition of GEF-H1/Rac1 
interaction than the previously made inhibitory peptide. There is also potential for 
blocking other GTPase/GEF and GTPase/effector interactions that have similar binding 
interfaces. 
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PROJECT PURPOSE 
 
  
 The aim of this project was to synthesize potential inhibitory peptides that could 
block the interaction between Rac1 and GEF-H1. To accomplish this, Rac1 was 
expressed and purified, and GEF-H1 was obtained from a fellow member of the lab. 
Analysis and purification of peptides also required the use of analytical methods such as 
HPLC and MALDI. These proteins and peptides are now available to use in assays to test 
the inhibition ability of the peptides on the binding ability and function of GEF-H1. 
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METHODS 
 
 
 The primary preparative methods were solid phase peptide synthesis (SPPS) and 
protein expression & purification. Peptide purity and identity was assessed by high 
performance liquid chromatography (HPLC) and matrix assisted laser 
desorption/ionization was used to back up HPLC data with mass data. The two main 
routes of testing were pull down assays and fluorescence microscopy.  
 After research into the subject had been done and there was a plan of how to 
accomplish the goal, the first step was to produce the required materials. Since the aim of 
this project was to block interaction between Rac1 and GEF-H1 it was necessary to 
express Rac1 and GEF-H1 and also to synthesize candidates for inhibitory peptides. The 
lab in which this project took place was currently working on the expression of GEF-H1. 
The GEF-H1 used in assays was provided by Katryn Harwood. 
 
Cloning of Rac1 
 The wild type Rac1 I.M.A.G.E clone was obtained from Open Biosystems. 
Polymerase chain reaction (PCR) was used to amplify the full-length Rac1 cDNA, 
incorporating 5’ BamHI and 3’ EcoRI restriction sites. Following the PCR reaction the 
DNA was double digested with BamHI and EcoRI. The digested DNA was separated on 
a 1% agarose gel and the band containing the desired PCR product was excised and 
purified. This purified fragment was then ligated into a pGEX-6P1 vector using T4 
ligase. This vector contains a PreScission protease cut site.  
 Following ligation, a small amount of the plasmid was digested with BamHI and 
EcoRI to ensure it contained the desired insert. Once the insert’s presence was confirmed, 
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the plasmid was transformed into DH5α cells.  DH5α is a strain of E. coli that lacks recA 
and endA making them useful primarily for the expression of plasmid DNA. Once the 
cells had taken up the DNA they were plated on Luria broth (LB) agar plates that 
contained the antibiotic carbenicillin. The following day individual colonies were picked 
and grown up into 5 mL cultures. These cell cultures were pelleted, lysed and their DNA 
purified using a QIAGEN miniprep kit. The purified DNA was again checked for 
presence of the desired insert and sequenced by the Nucleic Acid Facility at UMass 
Medical School.  
 
Rac1 Expression 
 Protein expression was carried out in BL21 cells. BL21’s are a strain of E. coli 
that lacks lon and ompT making them useful for expression of protein. The purified 
plasmid from the DH5αs was transformed into BL21 cells. Colonies were allowed to 
grow overnight on an LB agar plate containing carbenicillin. Individual colonies were 
picked and grown into 5 mL cultures. The next day, 1 L of 2xYT (yeast tryptone) was 
inoculated with the BL21 cells from one of the 5 mL cultures. The cells were allowed to 
grow at 37
o
 C until they reached their exponential growth phase. This was determined by 
measuring the cultures optical density at a wavelength of 600 nm (O.D. 600). Once the 
O.D. 600 was between the values of 0.8 and 1.0 (indicating exponential growth) protein 
expression was induced using 0.1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG). 
The culture was allowed to grow at 20
o
C for another 4 hours. The cells were then 
centrifuged down, separated from the supernatant, flash frozen in liquid nitrogen and 
stored at -80
o
C. 
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Protein Purification 
 Purification of the protein was accomplished using immobilized glutathione beads 
and PreScission protease. The frozen cell pellet was thawed and resuspended in 25 mL of 
lysis buffer (50 mM Tris, 0.5 M NaCl, 0.1% Tween 20). To inhibit general protease 
activity 250 µL of 1 M PMSF was added to the resuspended cells. The cells were 
sonicated for 10 seconds five times to lyse the cells. 250 µL of 1 M DTT was added to 
the lysate as a reducing agent. The cells were then centrifuged for 1 hour at 35,000 rpm 
and 4
o
C. The clarified supernatant was then incubated for 2 hours with immobilized 
glutathione beads. After 2 hours the beads were filtered, washed once using lysis buffer 
and once using wash buffer #2 (50 mM Tris, 250 mM NaCl, 5 mM MgCl2, pH 8.1). The 
beads were then washed with PreScission Protease buffer (50 mM Tris, 150 mM NaCl, 1 
mM EDTA, pH 7.4) twice. Beads were then incubated overnight with 960 µL of 
PreScission Protease buffer and 40 µL of PreScission Protease.  After incubation the 
beads were filtered and washed twice with PreScission Protease buffer. Following 
cleavage, samples of every step of the purification process were run on a 12% SDS-
PAGE gel in order to determine where Rac1 ended up. Aliquots of the protein were 
made, flash frozen and stored at -80
o
 C for later use. 
 
Peptide Synthesis and Purification 
 Synthesis of the inhibitory peptide was done using solid phase peptide synthesis 
(SPPS). SPPS is the sequential addition of amino acids to a chain tethered to a solid 
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support. The amino acid chain can then be cleaved from the support. The support used 
during the course of this project was Rink Amide MBHA resin obtained from 
Novabiochem.  
 First the resin was deprotected of its Fmoc group using 20% piperidine (Pip) in 
N’N’-dimethylformamide (DMF) 2x 2 minutes. Following deprotection 4 equivalents of 
amino acid and 4 equivalents of coupling agent (HBTU or HATU) were dissolved in 0.4 
M N-methylmorpholine (NMM).  HBTU was used when coupling to a normal amino acid 
or to the resin; HATU was used when coupling to an N-methylated amino acid. This 
mixture was added to the resin and allowed to couple for 1.5 hours for regular coupling 
and 3 hours when coupling to N-methylated amino acids. This process was repeated until 
the desired amino acid sequence was made. Following the addition of the final amino 
acid, the Fmoc group is removed and the product is cleaved from the resin. The cleavage 
process was done using 1 mL of the cleavage cocktail [95:2.5:2.5 trifluoroacetic acid 
(TFA):H2O:triisopropylsilane (TIS)] for 1 hour. The resin was washed with 1 mL of 
TFA. Precipitation into ether was used for quick clean up of the peptides. Adding the 
cleavage mixture to cold diethyl ether causes the formation of the TFA salt which 
precipitates out of solution. When the peptide was cleaved with the Fmoc group still 
attached or when dealing with N-methylated peptides the cleavage mixture was removed 
using a rotary evaporator equipped with an acid trap that would collect the TFA. The 
dried peptide in either case was dissolved into acetonitrile (ACN)/H2O 0.1% TFA, frozen 
and finally lyophilized to give a powdery product. 
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N-Methylation of Asp on Solid Support 
 Some N-methylated amino acids, for example (Me)Leu and (Me)Ala, are 
commercially available. For N-methylated amino acids that were not commercially 
available a three step methylation process was used. This process was originally 
described by Stephen Miller and Thomas Scanlan [6]. First the amino acid was 
deprotected using 20% Pip in DMF 2x 2 minutes. The residue was then reprotected using 
133 mg of nitrobenzylsulfonyl chloride (NBS-Cl) and 133 µL collidine. The amino acid 
was then methylated using 174 mg methyl p-nitrobenzylsulfonate (Me-NBS) and 86 µL 
of 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (MTBD). Finally the NBS-Cl was 
removed using 140 mL of β-mercaptoethanol and 151 mL of 1,8-diaza-
bicyclo[5.4.0]undec-7-ene (DBU). The product is the N-methylated amino acid that can 
be coupled to the next amino acid using HATU. 
 
High Performance Liquid Chromatography (HPLC) 
 High performance liquid chromatography (HPLC) was used for both analysis and 
purification during the course of this project. The type of HPLC used during this project 
was RP-HPLC. An Atlantis C-18 column was used from Waters. Mobile phases used 
were 0.1% TFA in H2O and 0.1% TFA in acetonitrile (ACN). A gradient of Solvent A 
(0.1% TFA in H2O) to Solvent B (0.1% TFA in ACN) was used to elute the samples. A 
typical gradient was 15-85% Solvet B over the course of 20 minutes. Detection of 
compounds was accomplished using a Waters 2996 photodiode array detector which is 
able to measure reflected light from 200nm-600nm.  A Waters 474 scanning fluorescence 
detector was also used for detection of fluorescent compounds.  
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Matrix Assisted Laser Desorption/Ionization (MALDI) 
 Mass analysis of the peptides was done using matrix assisted laser 
desorption/ionization (MALDI). MALDI was performed by mixing the sample with a 
matrix of α-cyano-4-hydroxycinnamic acid in 1:1 ACN:water. The mixture was then 
spotted on a metal plate and placed in a dessicator to allow the solvent to dry leaving only 
the matrix and sample. A laser was then fired at the spot which ionizes the matrix 
allowing it to transfer its charge to the sample. Once the sample was charged, time of 
flight (TOF) mass spectrometry was used. This uses retention times based on how long a 
compound takes to travel a known distance to determine mass.  
 
Cell Permeability Tests 
 Purified K(MeL)V(MeF)F was labeled with N-methylanthranilic acid (MANT) 
and was tested for cell permeability in HeLa cells. Cells were incubated for 1 hour with 
100 µM and 10 µM MANT-K(MeL)V(MeF)F in Leibovitz L-15 media. Following 
incubation, the cells were washed three times with media to remove extracellular 
fluorophore. The cells were then examined by fluorescence microscopy. 
 
Binding Assays 
 25 µL  of GST-GEF-H1 fusion protein bound to immobilized glutathione beads 
was incubated for 1 hour with 100 µg of nucleotide free Rac1 in a buffer containing PBS, 
50 mM NaCl and 1 mM TCEP. This assay was done in presence or absence of inhibitory 
peptides. Peptides tested were the Gao et al W56 peptide (synthesized by the Peptide 
Core Facility), Ac-NLGLWDTAG-NH2, Ac-WDTAG-NH2, and Ac-W(MeD)T(MeA)G-
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NH2. All peptides were added at a concentration of 200 µM. After incubation, the beads 
were filtered from the liquid and washed twice with buffer containing PBS, 2 mM TCEP 
and 0.1% Tween 20. A 12% SDS-PAGE gel was run of the samples to view bound versus 
unbound protein. 
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RESULTS 
Rac1 Expression and Purification 
 Rac1 expression using E. coli cells was successful. The polymerase chain reaction 
gave one major product with a few truncated products (Fig. 10). The major product was 
sequenced after it had been purified and expressed in DH5α cells.  
 
Figure 10: Agarose gel of PCR product.  Lane 1: 1 kB Ladder.  Lane 2: 100 bp Ladder.   
 Lane 3: Rac1 PCR Product. 
 
The sequence obtained was compared to known sequences of Rac1 using New England 
Biolabs NEBcutter and NCBI BLAST. The sequence matched up with full length, wild 
type Rac1. 
 Purification of Rac1 done with immobilized glutathione beads and PreScission 
Protease was also successful. SDS-PAGE gels were run to show the cleavage of the Rac1 
from the beads. The gel (Fig, 11) that was run shows all steps of the purification process 
from left to right: molecular weight standard, cell lysate, cell pellet, clarified supernatant, 
supernatant after incubation with beads, wash #1, wash #2, wash #3, wash #4, unbound 
protein, cleavage wash #1, cleavage wash #2, bound protein.  
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Figure 11: SDS-PAGE gel of Rac1 purification. Lane 10 shows purified Rac1, Lane 13 shows GST 
that is still bound to the immobilized glutathione. 
 
 
Peptide Synthesis 
 The first peptides synthesized were the same as the β-amyloid peptides described 
in the Gordon et al paper. Their sequences were K(MeL)V(MeF)F and KLVFF. 
Fluorescently tagged versions of these peptides were also made. The purpose of making 
these peptides was to practice peptide synthesis skills with N-methylated peptides known 
previously to work and to test membrane permeability of these peptides. Following this, 
inhibitory peptides were synthesized using the described techniques. These were to be 
used in any functional or inhibitory assays. 
 
β-Amyloid Peptide  
 The first batch of K(MeL)V(MeF)F that was made was labeled with N-
methylanthranilic acid (MANT). It was analyzed by HPLC and was found to be of low 
purity. Low concentration of peptide prevented analysis by electrospray mass 
spectroscopy. The second batch of MANT-K(MeL)V(MeF)F behaved much more 
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reliably on the HPLC yet still had several impurities as can be seen from its HPLC 
chromatogram (Fig. 12). 
 
Figure 12: HPLC chromatogram of MANT-K(MeL)V(MeF)F batch 2.  
Product peak highlighted in red. 
 
Impurity Analysis 
 The largest impurity, seen at 15.946 min in Fig. 12 (batch 2) and the proposed 
product peak, seen at 17.021 min in Fig. 12, were analyzed by MALDI. The mass 
analysis showed that the product peak was of the correct mass and that the impurity peak 
was off by 10 mass units. Professor Miller proposed that this change in mass would 
coincide with DMF (a solvent used for washing the resin) cyclizing between MANT and 
the N-terminal amine in the presence of TFA (Fig 13). 
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Figure 13: MANT attached to a peptide plus DMF in the presence of TFA forms the cyclized 
compound seen at the right. 
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After revising the procedure to exclude washing with DMF and synthesizing batch 3 of 
MANT-K(MeL)V(MeF)F there was a large reduction in the amount of impurity at that 
retention time. There was still, however, a significant impurity with a retention time of 
around 14 min. This impurity was thought to be a deletion peptide caused by incomplete 
couplings. To remedy this a fourth and final batch of MANT-K(MeL)V(MeF)F was 
prepared using acetic anhydride to cap after each step. This capping step would prevent 
any unreacted amines from reacting at some point later during the synthesis. The result 
was a much cleaner peptide with fewer impurities (Fig. 14) and the correct mass as 
determined by MALDI (Fig. 15). In the data from the MALDI there are other noticeable 
peaks after the product peak. These are due to the fact that the sample was not desalted 
before analysis. 
 
Figure 14: HPLC chromatogram of MANT-K(MeL)V(MeF)F batch 4.  
Product peak highlighted in red. 
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Figure 15: MALDI of MANT-K(MeL)V(MeF)F. Correct mass peak (M) at 813. 835 is M+ sodium 
(Na), 851 is M+ potassium (K), 875 is M+ copper (Cu). 
 
 
Inhibitory peptides 
 Truncated versions of the Gao et al peptide were synthesized using the methods 
described. Peptides that were successfully synthesized were Ac-NLGLWDTAG-NH2, 
Ac-WDTAG-NH2 and Ac-W(MeD)T(MeA)G-NH2.  Difficulty optimizing HPLC for the 
peptides led to no chromatograms for the inhibitory peptides. The peptides were analyzed 
by MALDI prior to their acetylation. MALDI analysis (Fig. 16) showed that there was 
some amount of the correct peptide sequence for all inhibitory peptides, though the 
amount is difficult to quantify given the lack of HPLC data. 
 
Figure 16: MALDI of unacetylated WDTAG. Correct mass peak at 548, other large peaks are salts. 
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Purification of Inhibitory Peptides 
 Purification of the inhibitory peptides was left at precipitation into cold ether. 
This would remove the bulk of non-peptide impurities. Purification of the β-amyloid 
peptides was initially removal of TFA by rotary evaporation followed by the collection of 
individual peaks from the HPLC for analysis by MALDI. 
 
Cell Permeability Test 
 MANT-K(MeL)V(MeF)F was tested for cell permeability on HeLa cells as 
described previously. The excitation and emission wavelengths of MANT are similar to 
that of autofluorescence of the cells, but Fig. 17 shows that there is a definite increase in 
fluorescence dependant on concentration of MANT-K(MeL)V(MeF)F (Fig.17). Figure 17 
also shows effective nuclear exclusion as can be seen by the darker spots in the middle of 
the cells. 
 
Figure 17: Cell permability test using MANT-K(MeL)V(MeF)F. Left is untreated HeLa cells.  Middle 
panel is cells treated with 10 µM peptide. Right panel is cells treated with 100 µM peptide. 
 
 
Binding Assay 
 The binding assay that was performed was inconclusive. As can be seen from Fig. 
18 there is no binding of GEF-H1 to Rac1 when there was no inhibitory peptide present. 
There also appeared to be no binding in the lanes treated with peptide. The untreated 
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protein was supposed to act as a positive control and without it there is no way to tell if 
there was any inhibition caused by the inhibitory peptides. 
 
 
Figure 18: Preliminary inhibition assay using synthesized peptides. Lanes were loaded as follows. 1: 
Benchmark Ladder 2: Untreated Unbound (UB) 3: Untreated Bound (B) 4: Gao et al Peptide UB 5: 
Gao et al Peptide B 6: NLGLWDTAG UB 7: NLGLWDTAG B 8: WDTAG UB 9: WDTAG B 10: 
W(MeD)T(MeA)G UB 11: W(MeD)T(MeA)G B 12: Rac1 13: GEF-H1 14: Benchmark Ladder 
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DISCUSSION 
 
Proteins 
 Initial attempts to purify Rac1 using a pGEX-4T vector, which contains a 
thrombin cleavage site, were ineffective. Thrombin has to be purified using benzamidine 
sepharose beads which experience a lot of unspecific binding. As a result of this, there 
was marked loss of Rac1 during purification. The switch to a pGEX-6P1 vector which 
contains a PreScission Protease site proved to be much more effective. The reason for 
this being that PreScission Protease is also expressed as a GST fusion protein. This 
allows it to cleave Rac1 from the glutathione beads then attach to the beads itself, 
effectively cleaving and purifying itself out in one step. The Rac1 that was expressed and 
purified during the course of this project is the right construct and has shown to be active 
in experiments done by other members of the lab for different purposes. The protein is in 
frozen aliquots and ready for use in any number of inhibition assays. The limiting factor 
that prevented assays from being done was active GEF-H1. The GEF-H1 was expressed 
and had the right sequence. The problem came when attempting to remove it from the 
immobilized glutathione beads. The PreScission Protease that was used to cut it from the 
beads was found to be inactive, therefore the GEF-H1 remained stuck to the beads. In the 
time spent trying multiple times to cleave the protein from the beads there was a 
significant amount of degradation of the protein. This explains the lack of activity seen in 
the GEF-H1/Rac1 pulldown assay (Fig. 18). 
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Peptides 
 Based on previous studies it is known that an inhibitory peptide can block the 
interaction between Rac1 and GEF-H1. The crystal structure of Rac1 and TiamI, which 
interacts in the same way as GEF-H1, shows that there is a portion of the inhibitory 
peptide made by Gao et al that does not come in contact with the GEF at all. This would 
lead us to believe that the Ac-NLGLWDTAG-NH2 peptide would block the interaction 
just as well. There is also a significant chance that the shorter truncation, Ac-WDTAG-
NH2, would work also. This is because the most significant attachment points to the GEF 
seem to be at N52, W56 and G60.  N-methylation should also increase activity of the 
inhibitor because it will reduce the entropic cost of forming an extended conformation.  
 The problem with the N-methylation and with the sequences of the peptides is 
that synthesis, purification, and analysis become more difficult. Synthesis of N-
methylated peptides requires longer coupling times which still do not necessarily go to 
completion because of the nature of the secondary amine found on N-methyl amino acids. 
When an amino acid is not commercially available with the N-methyl substitution the 
problem of methylating it arises. These problems are easily fixed, but the fix can be time 
consuming. 
 Synthetic obstacles aside, the purification and analysis of these peptides has 
become the largest problem. The inhibitory peptides would not run reliably on the HPLC 
making it difficult to assess the purity of the compounds. This was a problem due more 
likely to the sequence than the N-methylation because the N-methylated β-amyloid 
peptide was easy to optimize on HPLC. Furthermore, the inhibitory peptides had to be 
analyzed by MALDI before acetylation. After acetylation the peptides were more 
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difficult to ionize and as a result would not show as easily by MALDI. Though these 
problems have potential solutions there was not enough time in the scope of this project 
to optimize them. 
 
Cell Permeability 
 Testing of MANT-K(MeL)V(MeF)F on HeLa cells showed that the peptide is cell 
permeable. The data showed an increase in fluorescence, but that is difficult to quantify 
given the similarity between background autofluorescence of the cells and the fluorescent 
spectra of MANT. What is important is the nuclear exclusion that was seen. This shows 
that the peptide is in the cells as opposed to attached to the surface. Had it not been 
permeable, there would be no dark spot where it was left out of the nucleus. Attempts 
were made to couple K(MeL)V(MeF)F to the bright green fluorophore BODIPY-FL 
(Invitrogen) and a bright near-IR oxazine derivative prepared by a member of the lab. 
Coupling to BODIPY-FL was successful, but the treatment with TFA to cleave the 
peptide from the resin inactivated its fluorescence (data not shown). The oxazine 
derivative was stable to TFA, but there was little coupling to the peptide sequence (data 
not shown). No attempts were made to label the inhibitory peptides due to inability to 
purify and analyze properly. 
 
Future Research 
 The proteins and peptides made during this project will be useful to future 
experiments. The Rac1 is functional and the inhibitory peptides are of the correct 
sequence. The peptides will require some equipment optimization to get them to a desired 
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purity and to analyze their mass after acetylation. Provided that functional GEF-H1 can 
be obtained, the peptides will be very useful in binding inhibition assays as well as assays 
to test for GEF-H1 functionality. Given the proper amount of time one would be able to 
determine whether N-methylated peptides are good candidates for blocking these types of 
interactions. 
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